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Treatment of progressive multiple sclerosis: what works, 
what does not, and what is needed
Anthony Feinstein, Jenny Freeman, Albert C Lo
Disease-modifying drugs have mostly failed as treatments for progressive multiple sclerosis. Management of the disease 
therefore solely aims to minimise symptoms and, if possible, improve function. The degree to which this approach is 
based on empirical data derived from studies of progressive disease or whether treatment decisions are based on what 
is known about relapsing-remitting disease remains unclear. Symptoms rated as important by patients with multiple 
sclerosis include balance and mobility impairments, weakness, reduced cardiovascular fitness, ataxia, fatigue, bladder 
dysfunction, spasticity, pain, cognitive deficits, depression, and pseudobulbar affect; a comprehensive literature search 
shows a notable paucity of studies devoted solely to these symptoms in progressive multiple sclerosis, which translates 
to few proven therapeutic options in the clinic. A new strategy that can be used in future rehabilitation trials is therefore 
needed, with the adoption of approaches that look beyond single interventions to concurrent, potentially synergistic, 
treatments that maximise what remains of neural plasticity in patients with progressive multiple sclerosis.
Introduction
More than 20 years have passed since the introduction of 
the first disease-modifying treatment for multiple 
sclerosis, interferon beta-1b.1 Since then, nine further 
treatments have been approved and entered the market. 
All these drugs are for relapsing-remitting multiple 
sclerosis (RRMS), apart from interferon beta-1b 
(Betaseron), which has also been approved for use in 
secondary progressive multiple sclerosis (SPMS), but 
does not delay disability progression.2 Therefore, the half 
of patients with multiple sclerosis who have progressive 
disease have been left behind by the therapeutic 
bandwagon. This situation raises the question of how we 
can help patients with primary progressive multiple 
sclerosis (PPMS) and SPMS. Although research is 
ongoing to find a treatment that could halt further 
deterioration in a disease that has already entered a 
progressive stage, in the meantime patients and their 
clinicians only have symptomatic treatment options. As 
we will make clear in this Series paper, many treatments 
and strategies are available for a disease with such diverse 
symptoms. However, the degree to which existing 
therapeutic approaches are based on empirical data 
derived from clinical trials confined to patients with 
progressive disease remains unclear. A critical review of 
the evidence is therefore timely. In the absence of disease-
modifying treatments, what works symptomatically and 
what does not take on an even greater salience.
To choose which symptoms to include in this Series 
paper, we noted the views of patients with multiple 
sclerosis who have rated their symptoms in their perceived 
order of importance.3 We have also linked these symptoms 
to quality-of-life indices4 and have added our opinions 
regarding symptom significance, based on our clinical 
experience. The result is a Series paper that encompasses 
treatments for the following multiple sclerosis-related 
health issues: balance and mobility impairment, weakness, 
reduced cardiovascular fitness, ataxia, fatigue, bladder 
dysfunction, spasticity, pain, cognitive deficits, depression, 
and pseudobulbar affect. Prevalence rates and a summary 
of treatment options for each symptom are shown in tables 
1 and 2.5–59 We will conclude with some thoughts and 
recommendations about how future rehabilitation studies 
should proceed, derived from an existing initiative: the 
multinational Progressive Multiple Sclerosis Alliance.60
Balance and mobility impairment
Multiple sclerosis causes a wide range of neurological 
deficits, which often interact to cause mobility 
difficulties. Within 10–15 years of disease onset, 80% of 
patients have walking difficulties,5–7 which is of major 
concern to people with the disorder who report mobility 
as their most valued bodily function.3 An important 
contributor to mobility difficulties is impaired balance. 
Roughly 75% of people with multiple sclerosis report 
balance problems during the course of their disease,8 
even in the very early stages,5 with more impairment in 
people with progressive forms of multiple sclerosis than 
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Frequency
Mobility impairment 80%5–7
Balance impairment 75%8
Weakness 70%9
Ataxia 80%10,11
Fatigue 80%12
Bladder dysfunction 58–75%13,14
Spasticity 60–90%15
Pain 55–70%16
Cognitive dysfunction 60–70%17,18
Depression 25–50%19
Pseudobulbar affect 10%20
Table 1: Symptom frequency in progressive multiple sclerosis
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in those with RRMS.61 Impaired balance is characterised 
by increased sway in quiet stance, delayed anticipatory 
and automatic postural adjustments, and reduced ability 
to move towards the limits of stability.8 Poor balance 
performance on static and dynamic balance tests is 
associated with falls, with more than 50% of affected 
individuals falling within a 6-month period62 and 29–45% 
prone to recurrent falls.63 Importantly, people with 
multiple sclerosis have a twofold increased risk of fall-
related injuries compared with healthy individuals,64 and 
a fear of falling that can lead to a loss of confidence and 
restriction in activity levels.65
In view of the widespread and variable nature of CNS 
damage in multiple sclerosis, the cause of impaired 
balance and mobility is probably multifactorial and 
hypotheses about the key mechanisms vary. Some people 
believe that impaired central integration of visual, 
vestibular, and somatosensory input is key, whereas 
others suggest that the cerebellum could be the main 
contributor.66 Cognitive resources are also needed for 
postural control, with more difficult postural tasks 
requiring greater cognitive processing than simpler 
tasks. A meta-analysis assessing risk factors associated 
with falls showed that a progressive disease course is 
associated with a twofold increased risk of falling 
compared with a relapsing-remitting disease course.63
A range of interventions aimed at enhancing balance in 
standing and walking are used in clinical practice, the 
most common of which is physiotherapy. A systematic 
review comprising 11 randomised controlled trials,21 of 
which only one was restricted to progressive disease,22 
concluded that physiotherapy has small, but significant, 
beneficial effects on balance in those with mild to moderate 
disability, but evidence for the effects in severely disabled 
Trial type Endpoint 
(primary/
secondary)
Benefit? Multiple sclerosis disease course
Balance impairment
Specific balance exercises RCT Primary + RRMS and progressive MS (not analysed separately)21
Physiotherapy exercises RCT Primary + RRMS and progressive MS (not analysed separately)21
Physiotherapy exercises Pilot RCT Secondary ± PPMS and SPMS22
Mobility impairment
Treadmill training RCT Primary + RRMS and progressive MS (not analysed separately);23 SPMS24
Physiotherapy RCT Primary + RRMS and progressive MS (not analysed separately)21
Aerobic exercise training (eg, leg and/or arm 
cycle ergometry)
Pilot RCT Secondary + SPMS25
Progressive resistance training RCT Secondary ± RRMS and progressive MS (not analysed separately)10,26
Exercise training RCT Primary and 
secondary
± RRMS and progressive MS (not analysed separately)6
Weakness
Progressive resistance training RCT Primary + RRMS and progressive MS (not analysed separately)26
Physiotherapy exercises RCT Primary + RRMS and progressive MS (not analysed separately)26
Aerobic exercise training RCT Secondary + RRMS and progressive MS (not analysed separately)26
Locomotor training RCT Secondary ± RRMS and progressive MS (not analysed separately)26
Cycle ergometry RCT Primary + RRMS and progressive MS (not analysed separately)26
Combination training (eg, cycle ergometry 
and pylometrics)
RCT Primary ± RRMS and progressive MS (not analysed separately)26
Reduced aerobic capacity
Aerobic exercise training (eg, leg and/or arm 
cycle ergometry)
RCT Primary + RRMS and progressive MS (not analysed separately)26
Aerobic exercise training (eg, leg and/or arm 
cycle ergometry)
Pilot RCT Primary ± SPMS25
Combined aerobic and resistance training RCT Primary ± RRMS and progressive MS (not analysed separately)26
Ataxia
Medication
Isoniazid and pyridoxine Crossover Primary ± RRMS and progressive MS (not analysed separately)11
Cannabinoids RCT Secondary ± RRMS and progressive MS (not analysed separately)27
Surgical interventions
Thalamotomy versus deep-brain 
stimulation
Comparative Primary ± RRMS and progressive MS (not analysed separately)11
Physiotherapy/rehabilitation Comparative Secondary ± RRMS and progressive MS (not analysed separately)28,29
(Table 2 continues on next page)
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Trial type Endpoint 
(primary/
secondary)
Benefit? Multiple sclerosis disease course
(Continued from previous page)
Fatigue
Medication
Amantadine RCT Primary ± RRMS and progressive MS (not analysed separately)30
Carnitine RCT Primary ± RRMS and progressive MS (not analysed separately)31
Energy conservation programme RCT Primary ± RRMS and progressive MS (not analysed separately)32
Energy conservation programme Crossover Primary ± SPMS33
Aerobic exercise training RCT Secondary ± RRMS and progressive MS (not analysed separately)26,34
Aerobic exercise training Pilot RCT Secondary ± SPMS25
Progressive resistance training RCT Secondary ± RRMS and progressive MS (not analysed separately)26
Bladder dysfunction
Botulinum toxin RCT Primary + Not specified35
Portable bladder ultrasound Longitudinal Primary ± Not specified36
Percutaneous abdominal stimulation RCT crossover Primary – Not specified37
Pelvic floor muscle training and electrical 
stimulation
Longitudinal Primary – Not specified38
Solifenacin Longitudinal Primary + Not specified39
Spasticity
Botulinum toxin and physiotherapy RCT Primary + PPMS40
Sports climbing; yoga RCT Primary – RRMS and progressive MS (not analysed separately)41
Transcutaneous electrical stimulation Crossover Primary – Not specified42
Functional electrical stimulation cycling Longitudinal Secondary – PPMS and SPMS43
Naltrexone Longitudinal Secondary + PPMS44
Nabiximol RCT Primary + Not specified27,45
Pain
Treadmill training, bodyweight-supported/ 
robot-assisted training
RCT Secondary + PPMS and SPMS46
Transcutaneous electrical nerve stimulation RCT Primary and 
secondary
– Not specified47,48
Exercise, massage RCT Primary + RRMS and progressive MS (not analysed separately)49
Vibration therapy and exercise RCT Secondary + Not specified50
Intrathecal baclofen and morphine Retrospective Primary + SPMS51
Nabiximol RCT Primary + Not specified45
Cognitive dysfunction
Medication
l-amphetamine RCT Primary + RRMS and progressive MS (not analysed separately)52,53
Donepezil RCT Primary – RRMS and progressive MS (not analysed separately)54
Cognitive retraining RCT Primary + RRMS and progressive MS (not analysed separately)55
Cognitive retraining RCT Primary + RRMS and progressive MS (not analysed separately)56
Exercise RCT Secondary + PPMS and SPMS25
Depression
Medication
Desipramine RCT Primary ± Not specified57
Paroxetine RCT Primary ± Not specified57
Cognitive behaviour therapy RCT Primary + RRMS and progressive MS (not analysed separately)58
Exercise RCT Secondary + PPMS and SPMS25
Pseudobulbar affect
Medication
Dextromethorphan plus quinidine RCT Primary + Not specified59
RCT=randomised controlled trial. RRMS=relapsing-remitting multiple sclerosis. MS=multiple sclerosis. PPMS=primary progressive multiple sclerosis. SPMS=secondary 
progressive multiple sclerosis. +=Yes. –=No. ±=Equivocal. 
Table 2: Studies of symptomatic management in chronic progressive multiple sclerosis
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people is scarce. A range of physiotherapy techniques were 
used in these trials, including specific balance exercises, 
neuromuscular facilitation, resistance training, and 
aerobic training, but their relative effectiveness is not 
known either for those with RRMS or progressive disease.
Neural plasticity is enhanced following task-specific 
rehabilitation.67,68 Therefore, balance and mobility 
interventions are thought to provide the appropriate task-
specific stimuli to help neural re-organisation of central 
sensory integration, thereby leading to improved stability 
(panel 1). Although greater benefits are generally believed 
to be gained from balance and mobility interventions in 
the earlier phases of multiple sclerosis, there is 
encouraging evidence that the capacity for neuroplasticity 
and motor learning seems to continue even in those with 
more severe disability.68 For example, a systematic review 
of studies investigating the effect of treadmill or robot-
assisted training provides modest evidence to show that 
improvements in quality of life and gait can occur in 
those patients with high levels of disability.23 Of the eight 
studies included, two were small single-group studies 
that restricted their sample to patients with progressive 
disease.24,69 However, whether or not there is a point at 
which neural reserve becomes too low for neural 
plasticity to promote functional change remains 
unknown. Peripheral physiological changes, such as 
muscle endurance, also contribute to changes in balance 
status. So too does the ageing process, in which 
reintegration of sensory information becomes more 
difficult and attention demanding for older adults. This 
situation has substantial relevance for people with 
progressive multiple sclerosis who are more likely to be 
older patients with a greater disability burden.
In summary, insufficient evidence exists to support 
balance or mobility retraining as effective interventions 
for people with progressive disease, although data from 
mixed patient samples are promising. Future research 
should establish whether or not those with progressive 
multiple sclerosis, and at different levels of disability, 
respond differently to these interventions, and if so 
whether and when interventions should be re-focused on 
compensatory rather than restorative strategies.
Weakness
Weakness is present in up to 70% of people with multiple 
sclerosis.9 Reduced muscle strength seems to mainly 
affect the lower limbs, although weakness in the upper 
limbs, trunk, and respiratory muscles is also 
problematic.10,70,71 Muscle strength is important since it is 
associated with mobility difficulties (reduced gait speed 
and endurance), balance, and functional activities.72 The 
relative contribution of the disease process and reduced 
physical activity levels to weakness remains unclear; it 
might differ substantially between disease phenotypes 
and needs further investigation.
Physical therapy interventions, such as resistance 
training and task-specific training, are the mainstay of 
interventions. A systematic review and meta-analysis10 
provides strong evidence in support of the use of 
resistance training (eg, weight machines, free weights, 
and resistance bands) to improve lower limb strength, 
although the evidence for its effect on upper limb 
strength and mobility, functional capacity, and balance is 
modest. Other forms of strength training (eg, locomotor 
training, cycling, and aquatics) can also enhance lower 
limb strength.26 Small but clinically meaningful improve-
ments in walking mobility for mixed disease types have 
been shown by a systematic review and meta-analysis of 
22 published studies investigating exercise training, 
although no significant effect was recorded in the groups 
composed solely of people with progressive disease.6 
However, the authors emphasise that this finding might 
be indicative of the small number of studies (ie, four) 
Panel 1: Case study 1—physical rehabilitation
A 50-year-old man with a 25-year history of multiple sclerosis that had entered a 
secondary progressive phase 15 years previously was referred after being admitted to 
hospital because of frequency of micturition, confusion, and hallucinations. Symptoms 
were attributed to pyelonephritis and antibiotics initiated. His history showed that he had 
been wheelchair bound for the past 12 years, but had managed to live alone at home in an 
adapted flat with assistance and support from social services and his adult children when 
it came to shopping and housework. However, in the past 12 months his physical 
condition had started to deteriorate and he was struggling to maintain independence in 
many self-care activities.
Unable to return home with his existing level of function, he was transferred to a 
rehabilitation unit where he was assessed as being dependent for all self-care, transfers, 
and mobility. Physical examination showed spastic paraparesis, trunk and upper limb 
weakness, poor sitting balance, bladder hyper-reflexia with urinary tract infection, 
constipation, pressure sore on the right heel, changed sensation in the lower limbs, low 
activity tolerance, cognitive impairment, depression, and fatigue. He scored 8·0 on the 
Expanded Disability Status Scale and subjectively rated his quality of life as poor. Working 
with the patient, his rehabilitation team established a set of goals that included returning 
home with minimum assistance for self-care and domestic tasks, independence in 
transfers and in performing a home exercise programme, and improved bladder, bowel, 
and muscle tone management.
To achieve these goals, an intensive multi-disciplinary programme was started that 
involved re-education with respect to self-care and domestic activities, transfers and 
sitting balance, pressure care, and prevention and treatment of urinary tract infections, 
which included self-medication. A regimen of suppositories and regular aperients was 
started and advice given for continuation post-discharge. Following a psychiatric 
assessment, anti-depressant treatment was started, and simple, basic training provided in 
relaxation techniques to cope with anxiety and stress. A meeting was also held with the 
patient and his caregivers and family to provide education pertaining to cognitive 
compensatory strategies to offset, in part, his memory dysfunction. Finally, referrals were 
made to a local wheelchair service for wheelchair adaptations and a pressure-relieving 
cushion, and to community services for home modifications that included rails to be 
fitted beside the toilet and the installation of an intercom system.
After 4 weeks of inpatient rehabilitation, the patient was discharged home because he had 
achieved his short and intermediate goals of improving functional independence and 
quality of life. Close liaison with community services was judged to be crucial to ensure 
safety in the home and the carryover and sustainability of the many improvements gained.
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focused on progressive disease, rather than a true 
differential effect of exercise training, and conclude that 
further research is needed in this disease subtype before 
recommendations can be made.6
Preliminary research suggests that exercise might 
delay disease progression by reducing inflammation and 
encouraging neuronal repair. In view of the fact that 
exercise studies done so far typically comprise samples of 
mixed disease types, a pressing need exists to focus on 
progressive disease since many of the issues related to 
deconditioning might be especially pertinent to this 
phenotype.
Weakness in multiple sclerosis was, until fairly recently, 
not thought to be amenable to drug treatment.7 However, 
a recent Cochrane review of 4-aminopyridine shows that, 
in a subset of patients, this well tolerated drug improved 
walking speed and muscle strength of the lower 
extremities.73 In-vitro studies suggest that the likely 
mechanism of action is improved impulse conduction 
through demyelinated lesions.73 Of 16 clinical studies of 
4-aminopyridine, only one restricted sample selection to 
people with progressive disease and this study did not 
measure muscle strength or mobility.74 Therefore, at 
present, no recommendations can be made for those 
with progressive disease in relation to the effect of 
4-aminopyridine on weakness or mobility.
In summary, an absence of clinical trials in people with 
progressive disease means that insufficient evidence 
currently exists to support either medication or resistance 
training as effective interventions for improving mobility, 
functional capacity, or upper limb strength in people 
with progressive multiple sclerosis. Existing evidence 
supports the use of progressive resistance training to 
improve lower limb strength, but replication studies are 
needed to confirm this idea.
Reduced cardiovascular fitness
Compared with people with other chronic diseases, 
individuals with multiple sclerosis are at the lowest end of 
the physical activity scale (ie, they do the least amount of 
physical activity).75 A meta-analysis provides strong 
evidence that aerobic exercise training, such as cycle 
ergometry, undertaken at least two to three times per 
week for 30–60 min at a moderate intensity can effectively 
improve aerobic capacity and power output in people with 
mild to moderate disability.26 Most of these studies include 
both RRMS and progressive disease, so whether those 
with progressive multiple sclerosis, or severe disability, 
also benefit remains uncertain. Encouragingly, evidence 
from recent small-scale exercise studies of people with 
progressive multiple sclerosis, with moderate and severe 
disability, suggests that endurance training can improve 
aerobic capacity,25,76 leading to an increase in walking 
distance.25 Low dropout rates and good levels of adherence 
also provide cautious optimism that this intervention is 
feasible and acceptable in those with progressive disease.77 
Further research is needed to confirm these findings.
In summary, evidence is accumulating to support the 
effectiveness of aerobic exercise training in people with 
progressive disease. However, so far the studies are too 
few and lack the methodological rigor to inform clinical 
practice.
Ataxia
An estimated 80% of patients with multiple sclerosis 
experience ataxia at some point in their disease course.10,11 
A range of treatments are available, including 
pharmacotherapy (eg, isoniazid, pyridoxine, and 
cannabis), stereotactic neurosurgery (thalamotomy or 
deep-brain stimulation), and neurorehabilitation. 
However, treatment remains challenging. The only 
Cochrane review that has focused specifically on ataxia in 
multiple sclerosis concluded that insufficient evidence 
exists for the efficacy and tolerability of pharmacotherapies 
to treat this aspect of the disease.11 This is also the case 
for neurosurgery and neurorehabilitation, despite the 
occasional promising result.28,29 Moreover, no studies 
have focused on progressive multiple sclerosis.
Treatments for ataxia can be broadly divided into those 
that are compensatory and those that are restorative in 
nature. Compensatory approaches involve teaching 
individuals how best to manage their ataxia. A range of 
strategies include the following: decomposition of 
movement into simpler single joint movements; visual 
and verbal cues to help walking speed and stride length; 
biofeedback through virtual reality or electromyography; 
and aids to help posture, balance, and mobility. Lycra 
garments have also been used to improve trunk stability 
and function, although only preliminary evidence 
regarding their effectiveness exists at present.78 
Interventions that increase inertia by loading the limbs 
or trunk with weights have shown varied success.28 
Cooling of a limb can also temporarily reduce cerebellar 
tremor by increasing muscle stiffness or reducing any 
one or more of muscle thixotropy, nerve conduction 
velocity, and muscle spindle afferent feedback.28
Evidence supporting the effectiveness of restorative 
approaches is moderate at best. Biofeedback, such as that 
linked to computer games that require balance and 
multi-segment coordination, has proved helpful in some 
patients to improve balance and falls.79 Other studies 
have assessed the effect of multicomponent approaches 
on balance and walking, such as balance activities 
combined with ocular exercises,80 or a combination of 
conventional physiotherapy strength and balance 
exercises.22 Small-scale studies of adaptive robot therapy 
(that enables highly repetitive, intensive, and interactive 
activity) have shown some success in improving manual 
dexterity and coordination of the upper limbs, indicating 
that patients can adapt by learning to predict the effects 
of perturbing forces.81 More recently, studies have 
explored the use of rapid transcranial magnetic 
stimulation (motor cortical stimulation), and have 
demonstrated an improvement in hand function 
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compared with controls.82 The mechanisms underlying 
these improvements remain unclear.
In summary, recommendations about the management 
of ataxia in people with progressive multiple sclerosis 
cannot be made because of insufficient research into 
this topic.
Fatigue
Fatigue occurs in up to 80% of patients with multiple 
sclerosis and is reported more frequently in progressive 
than in relapsing-remitting disease.12 It is an important 
determinant of quality of life, with two-thirds of patients 
reporting fatigue as one of their most troubling 
symptoms.83 Effective treatment remains scarce. 
Although several strategies are routinely used in clinical 
practice, treatment recommendations are based on very 
little scientific evidence. Systematic reviews provide 
some evidence in favour of drug therapies and energy 
conservation treatment, although studies have yielded 
mixed results.30–32 Results from a randomised controlled 
trial, and confirmed in a meta-analysis (albeit with a 
mixed disease type), support the potential benefits of 
exercise on fatigue.34,84 Randomised controlled trials of 
vestibular rehabilitation and patient education 
programmes that incorporate a cognitive behavioural 
approach also provide some evidence of benefit,85–87 as 
have some,88 but not other,89 multifaceted rehabilitation 
studies. Although small-scale studies of energy 
conservation techniques or exercise focusing solely on 
people with progressive multiple sclerosis have been 
undertaken,25,33 these are rare and typically assess only 
short-term outcomes. Caution should therefore be taken 
in the extrapolation of conclusions to this phenotype.
Successful treatment of fatigue with use of behavioural 
approaches is increasingly recognised to possibly affect 
the underlying biology. Therefore, future studies, in 
addition to focusing on progressive disease, should 
incorporate biomarkers to elucidate the potential 
mechanisms underpinning any observed behavioural 
changes.90 This approach has been used to a limited 
extent in patients with RRMS.91,92 Patients with subjective 
fatigue were given single doses of rivastigmine and 
3–4 diaminopyridine, with resultant improvements in 
brain activation patterns associated with information 
processing speed and motor activity, respectively.91,92
In summary, although some evidence supports the 
effectiveness of drug therapies and behavioural 
approaches such as energy conservation treatments in 
mixed patient samples, this finding has yet to be 
confirmed in patients with progressive disease.
Bladder dysfunction
Most people with multiple sclerosis experience bladder 
problems during their lives.13,14 These difficulties correlate 
highly with quality of life. Although moderate to severe 
bladder and bowel problems are common even in 
patients with a relatively recent diagnosis,93 studies do 
not generally distinguish between disease types when it 
comes to the frequency and severity of symptoms.
A reduction in the frequency of incontinence is 
important from a psychological and self-esteem 
perspective. In initial stages of bladder overactivity, 
pharmacological agents such as anticholinergics (eg, 
oxybutynin) and antimuscarinic agents (eg, solifenacin) 
are typically used.39 More recently, botulinum toxin 
injections have received US Food and Drug 
Administration approval for the treatment of urinary 
incontinence resulting from detrusor overactivity caused 
by multiple sclerosis. The study with the largest 
enrolment of participants with multiple sclerosis (n=154) 
did not provide information about disease course,35 but a 
smaller study of 43 patients did, although without 
providing a breakdown of the proportion of participants 
with RRMS, PPMS, and SPMS.94 Both these studies 
reported improvements in urinary incontinence with 
botulinum toxin treatment. 
Depending on severity, rehabilitative methods such as 
facilitated emptying through intermittent catheterisation 
or external compression are the approaches typically 
recommended for the management of neurogenic 
bladder. Assistive devices have been assessed to direct 
the timing of catheterisation, which is usually based on 
symptoms, post-void residuals, or a set schedule. Portable 
bladder ultrasound devices, which allow switching from 
a time-dependent to a volume-based catheterisation, 
have been shown to significantly reduce frequency of 
incontinence.36
The most frequently used method to assist bladder 
emptying is suprapubic bladder compression. This 
approach can be an alternative to intermittent 
catheterisation if residual volumes are sufficiently 
reduced, or if intermittent catheterisation is difficult 
because of other impairments such as problems with fine 
dexterity. A randomised controlled trial in patients with 
multiple sclerosis showed that, compared with no 
treatment, percutaneous stimulation (vibration) applied to 
the suprapubic region of the abdomen was effective in 
reducing residual volumes, but no effect was reported for 
abdominal pressure alone.37 Furthermore, despite the 
significant improvement in post-void residual volume, the 
frequency of micturition or incontinence did not change.
Pelvic floor rehabilitation for stress incontinence is one 
of the few rehabilitative training methods for bladder 
dysfunction in multiple sclerosis. A study of pelvic 
training using electrical stimulation and biofeedback for 
ten 30-min sessions reported better muscle strength and 
reduced frequency of incontinence with this 
approach.38 However, despite improvement in the 
functional capacities of the bladder, residual volumes did 
not significantly improve, which suggests that this therapy 
is best indicated for those with mild multiple sclerosis, 
without pelvic floor spasticity or detrusor sphincter 
dyssynergia. Once again, studies are few, and they have 
restricted their recruitment to those with RRMS.
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In summary, no treatment studies have focused 
exclusively on progressive multiple sclerosis patients 
with bladder dysfunction. As such, the effectiveness of 
the treatments and approaches summarised in this 
section remains unclear for people with progressive 
disease.
Spasticity
Spasticity in multiple sclerosis is a manifestation of 
disrupted descending motor pathways caused by axonal 
degeneration or demyelination. Around 60–90% of people 
with multiple sclerosis will develop spasticity during their 
lifetime.15 Spasticity can be localised, multifocal, or 
regional, and can add to impairment by reducing the 
range of movement across joints, increasing stiffness, and 
contributing to pain, contractures, and pressure sores 
(panel 1). Spasticity curtails social participation and 
reduces quality of life.15
Treatment approaches are often multidimensional and 
include oral pharmacological agents, invasive and 
surgical procedures, and various rehabilitative therapies.95 
A Cochrane review discussed the use of various 
pharmacological agents for multiple sclerosis, including 
baclofen, diazepam, dantrolene, and tizanidine (among 
others), but reported no specific findings related to 
spasticity in progressive multiple sclerosis.96 
A 6-month open-label study showed low-dose 
naltrexone effectively reduced spasticity in 40 patients 
with PPMS.44 A study that included 38 patients with 
SPMS showed that 15 sessions of physiotherapy in 
addition to botulinum toxin type A injection had superior 
effects to botulinum toxin alone.40 Another trial of 
patients with RRMS and SPMS compared the effects of 
two forms of aerobic physical activity—sports climbing 
and yoga—on spasticity.41 No significant effects on 
spasticity were recorded after 10 weeks, although yoga 
improved cognition and sports climbing lessened 
fatigue. Results from a range of neurostimulation 
techniques, used alone or in combination with other 
interventions, are more promising. For example, 
transcutaneous electrical stimulation applied for 8 h was 
more effective than was a 60-min treatment at reducing 
spasticity,42 and combination trials testing 2 weeks of 
intermittent transcranial magnetic theta burst 
stimulation plus exercise therapy decreased spasticity to 
a greater magnitude than did magnetic theta burst 
stimulation alone.97 In a study confined to five patients 
with PPMS or SPMS, 6 months of home-based functional 
electrical stimulation cycling (in which electrical pulses 
prompt the legs to “cycle” on an adapted, stationary, 
recumbent bicycle) did not reduce lower extremity 
spasticity, although the specific stimulated muscle 
groups did increase in strength.43
Patients with spasticity have looked to cannabis for relief. 
Cannabis contains more than 60 cannabinoids, of which 
tetrahydrocannabinol (which has psychoactive properties) 
and cannabidiol are the most abundant. Two forms of 
pharmaceutically manufactured cannabis are used by 
patients with multiple sclerosis, namely a mucosal spray 
(nabiximol [Sativex]) and pills (dronabinol [Marinol] and 
nabilone [Cesamet]). Another option is the garden-grown 
variety (which can be legal or illegal, depending on country 
or state of residence), which is smoked or, less frequently, 
ingested. Uncertainty surrounds the putative benefits of 
cannabis. A randomised controlled trial of 572 patients 
with multiple sclerosis with refractory spasticity showed 
significant add-on benefits with nabiximol.45 In a study 
design that was thought to replicate clinical practice, only 
those patients who had an initial reduction in spasticity of 
greater than 20% with nabiximol proceeded to the 
randomisation phase. Disease course was not specified, 
but a mean Expanded Disability Status Scale score of 6·0 
in study participants suggests that many of them had 
progressive disease. Nabiximol is licensed for the treatment 
of multiple sclerosis-related spasticity throughout Europe, 
Canada, and the USA. Notwithstanding these develop-
ments, a recent American Academy of Neurology critical 
review concluded that subjective improvements in 
spasticity with nabiximol were probably not matched by 
the objective data.27 The review also failed to find data to 
support the efficacy of smoked cannabis.27
In summary, the existing data from a small number of 
patients with progressive multiple sclerosis indicate that 
the addition of physiotherapy to botulinum toxin is 
superior to botulinum toxin treatment alone; home 
functional electrical stimulation cycling did not seem to 
be effective at reducing spasticity; no supporting data 
exist for the use of neurostimulation to reduce spasticity 
in the population with progressive multiple sclerosis; 
and opinions with respect to the efficacy of nabiximol are 
divided, in the context of no specific data for progressive 
multiple sclerosis.
Pain
A recent large systematic review16 of 28 prospective 
studies with 7101 participants indicated a pooled pain 
prevalence of 62·8%. Prevalence according to disease 
type was as follows: SPMS 69·8%, PPMS 70·3%, and 
RRMS 50%. Headache was the most common type of 
pain (42%), followed by extremity pain (26·6%), back 
pain (20%), painful spasms (15%), Lhermitte’s sign 
(16·6%), and trigeminal neuralgia (3·8%).16 Pain, when 
present, is rated by patients as one of their most 
challenging symptoms. It is associated with a poor quality 
of life and interferes with daily activities, especially as its 
severity increases.98,99
Treatment for pain is very much pharmacologically 
based. Pain medications can account for nearly 30% of 
all drug use for all multiple sclerosis symptoms,100 but 
patient satisfaction with their pain management is 
generally low.99 Nabiximol (Sativex) is judged to be 
effective by an American Academy of Neurology review 
committee, although there was no comment in relation 
to a particular disease course.27 Other medications shown 
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to be helpful for pain relief in multiple sclerosis (subtype 
not specified) are antidepressants, antiepileptic agents, 
opioids, and baclofen.51 Medication treatment trials in 
progressive multiple sclerosis are scarce, but in one 
study of SPMS, intrathecal baclofen and morphine were 
reportedly effective.101
Few rehabilitation studies of pain mention 
progressive disease; among those that do are treadmill 
training studies. A quality-of-life analysis of 13 patients 
with PPMS or SPMS who had undergone bodyweight-
supported treadmill or robot-assisted gait training 
showed that both training interventions resulted in 
significant longitudinal improvements in pain.46 A 
randomised controlled trial for back pain assessed the 
use of high-frequency (110 Hz) and low-frequency 
(4 Hz) transcutaneous electrical nerve stimulation in 
90 people with multiple sclerosis in which there was an 
inference of progressive disease without disease types 
being specified. The treatment was self-administered 
twice daily for 45 min per day, for 6 weeks.47 The most 
notable reduction in pain was recorded in the high-
frequency group. Similarly, 100 Hz transcutaneous 
electrical nerve stimulation has proven to be effective in 
reducing lower extremity pain following 8 h of 
stimulation in a group of patients in which disease type 
was not recorded.48
Exercise and massage are widely available interventions 
and a randomised study49 compared exercise (strength, 
stretching, endurance, and balance) versus standard 
massage. The data showed that massage alone or in 
combination with exercise resulted in significant 
reductions in pain compared with exercise alone.49 
Similarly, whole-body vibration therapy combined with 
exercise proved more effective than exercise alone in 
reducing pain secondary to spasm.50 Neither of these 
studies made reference to differential effects according 
to disease type.
In summary, data about rehabilitative interventions for 
pain in progressive forms of multiple sclerosis are scarce. 
Positive findings indicate that bodyweight-supported 
treadmill training can reduce pain. Although data from 
transcutaneous electrical nerve stimulation and exercise 
or massage studies also indicate beneficial effects, these 
findings have not been broken down according to disease 
type. The same limitations pertain to medication, with 
the exception of nabiximol and intrathecal baclofen with 
morphine.
Cognitive dysfunction
The prevalence of cognitive dysfunction varies from 
roughly 40% in RRMS to 60% in SPMS. Rates of 
dysfunction are higher in SPMS than in PPMS, whereas 
patients with RRMS have the lowest levels of 
impairment.17,18 The cognitive domains affected most 
frequently are those of information processing speed, 
memory, and executive function. MRI data show that as 
the disease progresses, the neural networks that underpin 
cognition become more disorganised.102 Excessive and 
more widespread recruitment of brain regions in SPMS 
indicate a failure of brain compensatory mechanisms and 
translate into greater cognitive dysfunction.102 Of 
particular interest are findings from resting state 
functional MRI in which dysfunction in the anterior 
components of the default mode network were recorded 
in patients with SPMS and PPMS relative to healthy 
controls.103 In turn, this dysfunction was also associated 
with more extensive cognitive decline. Yet although 
disease course predicts cognitive dysfunction, it cannot 
alone explain why cognition fails in some patients with 
progressive disease but not others. Here, the importance 
of cognitive reserve emerges; even in SPMS a lifetime of 
intellectual enrichment defined according to educational 
attainment and breadth of vocabulary mitigates, and in 
some cases prevents, cognitive decline.104
The ability of patients with multiple sclerosis to obtain 
and maintain employment, manage relationships, and 
complete everyday tasks is associated with their cognitive 
abilities (panel 2).105 In view of the widespread, real-
world functional implications of impairment, it follows 
that cognitive abilities are a major determinant of 
response to rehabilitation.106 In a telling example of how 
apparently diverse functional abilities are intertwined, 
in-patient, individualised multi disciplinary treatment 
led to significant improvements in patient mobility, but 
only in those without severe cognitive impairment.106
The pharmacological treatment of cognitive 
dysfunction in multiple sclerosis has yielded mixed 
results. Although negative studies predominate, a few 
tentative successes have been reported. Disease-
modifying therapies have proved disappointing, 
notwithstanding their ability to bring about improvement 
in brain MRI metrics. A trial of interferon beta-1b in 
217 patients with SPMS and moderate disability used a 
single cognitive measure, namely the 3·0 second Paced 
Auditory Serial Addition test, for which a trend towards 
improvement was noted over the course of 36 months in 
the treatment group, but not the placebo group.107 A 
double-blind, randomised, placebo-controlled trial of 
interferon beta-1b also did not offer any cognitive benefits 
to 73 patients with PPMS who were assessed over a 2-year 
period.108 More promising results have, however, been 
obtained from putative cognitive-enhancing agents in 
studies that focused on specific cognitive domains in 
patients with multiple sclerosis who were defined as 
impaired at study entry. Benefits have been reported 
from randomised controlled trials with a single dose of 
methylphenidate,109 4 months of modafinil,110 and 
l-amphetamine either given over 4 weeks or as four 
single doses.52,53 What makes the l-amphetamine result 
more intriguing is that a drug that ostensibly targets 
attention was found to have more widespread effects that 
included improvements in both verbal and visuospatial 
memory. However, no such benefits were reported with 
the memory-enhancing agent donepezil.54
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Recent results have suggested that cognitive retraining 
might, despite receiving negative to lukewarm Cochrane 
reviews, hold promise (panel 2).111 Reasons for this new-
found enthusiasm include modifications to the type of 
retraining offered, a willingness to look beyond 
randomised controlled trials to different approaches such 
as a controlled within-participant study design, and the 
ability to show changes in cerebral activation on 
functional MRI commensurate with the cognitive 
improvements. One study that holds particular promise 
for patients with progressive multiple sclerosis involved a 
mixed group of participants (17 with RRMS, four with 
PPMS, and seven with SPMS); the greatest benefit 
derived from the use of context and imagery to improve 
new learning was found in participants who had more 
severe impairments to start with.55 The same group went 
on to replicate this result in a larger randomised 
controlled trial of 86 patients with multiple sclerosis. Of 
the 45 participants in the active treatment group, eight 
had progressive disease (one PPMS, six SPMS, and one 
progressive relapsing).56 Although no specific treatment 
group interaction was sought or reported in either of 
these studies, in view of what is known about memory 
impairment across the range of disease course, the 
assumption that benefits accrued to many of the patients 
with progressive disease is reasonable. The same 
conclusions could be inferred from a study that also 
focused on memory deficits, but included functional MRI 
correlates obtained before and after cognitive retraining. 
Improvements in memory were linked to increased 
cerebral activation during performance of a cognitive 
task, but only in the eight participants who had received 
treatment, three of whom had progressive multiple 
sclerosis (no further subdivision was provided).112 
However, the positive interpretation of findings like these 
cannot obscure the fact that much remains unknown. As 
with the medication trials, the data are heavily skewed 
towards patients with RRMS and even here, it is unclear 
how long benefits remain following treatment cessation 
or the degree to which improvement on one cognitive 
measure translates into enhanced day-to-day functioning.
Improvements in cognition, or a halt to the progression 
of cognitive decline, depend on the degree to which brain 
plasticity has been compromised. Here, as the functional 
brain imaging data show, patients with progressive 
multiple sclerosis—especially SPMS—are affected to a 
greater extent than are those with RRMS. However, some 
tentative evidence suggests that cerebral compensatory 
mechanisms even in these patients remain viable and 
receptive to therapeutic interventions. The first piece of 
supporting evidence comes from the cognitive reserve 
literature. If intellectual enrichment can prevent or delay 
the onset of cognitive decline, might not an intervention 
that promotes a more cognitively stimulating lifestyle 
halt or even reverse the deficits that are already apparent? 
Although the answer to this question is not yet known in 
progressive multiple sclerosis, what is more certain is 
that increased physical activity carries the promise of 
cognitive benefits. In a randomised controlled trial of 
42 patients with progressive multiple sclerosis (31 SPMS 
and 11 PPMS) with moderate physical disability 
(Expanded Disability Status Scale score 4–6) significant 
improvements in aerobic fitness and several secondary 
outcome measures, including indices of cognition, were 
noted in those patients assigned to various forms of 
exercise rather than a waitlist group.25 The study was 
notable for being the first that specifically targeted 
physical function and cognition in patients with 
progressive multiple sclerosis.
In summary, insufficient evidence currently exists to 
support medication or cognitive retraining as effective 
treatments for cognitive impairment in progressive 
multiple sclerosis (panel 2), although promising data for 
cognitive retraining in mixed samples of patients with 
multiple sclerosis are duly noted. Exercise seems to 
benefit cognition, but replication studies are needed and 
the best type of exercise needs to be clarified.
Depression
Between a third and half of all patients with multiple 
sclerosis will develop major depression during the course 
of their lives.19 Unlike cognition, however, the association 
with disease course is equivocal.113,114 What this uncertainty 
indicates is that the underlying cause of depression is 
Panel 2: Case study 2—cognitive dysfunction
A 42-year-old married man with three young children and a 5-year history of primary 
progressive multiple sclerosis, with a current Expanded Disability Status Scale score of 5·5, 
presented with a report of work-related problems. He had always taken his intellectual 
abilities for granted, having done well at university and thereafter progressed rapidly up 
the corporate ladder. However, he now reported that tasks that he had always taken for 
granted were taking much longer to complete, which meant having to take work home in 
the evenings and on weekends. As a result, he now had less time to spend with his wife 
and children, leading to a strained home life. Adding to his worries was the appearance of 
small work-related errors that had come to the attention of the company’s senior 
management, who had called him in to express their concerns. Psychiatric inquiry ruled 
out the presence of a major depression, and a Mini Mental State Examination score was 29 
out of 30, the one point lost for delayed verbal recall. In view of the primary cognitive 
nature of the patient’s complaints, he was referred for neuropsychological assessment. The 
results showed superior premorbid intelligence and a generally intact cognitive profile, 
apart from indices of information processing speed and working memory in the 
borderline-normal range. Notwithstanding the absence of failure on any one cognitive 
test, these results suggested substantial cognitive decline, albeit mitigated by good 
cognitive reserve. This fall-off in function was judged to be sufficient to compromise the 
patient’s ability to manage his intellectually challenging, fast-paced job. A trial of donepezil 
treatment failed to bring about improvement. A combination of methylphenidate and 
12 weeks of cognitive retraining produced modest benefits only marginally improving 
work performance. At that point, with the patient’s consent, his company was approached 
with a recommendation for worksite accommodations, in particular a reduced workload, 
more time to complete tasks, and a maximum 36-h working week. The company agreed to 
a 6-month trial period that proved successful. It was then agreed between all parties that 
the situation would be reviewed annually.
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complex, with explanations less reductionist than those 
used to explain cognitive dysfunction. The findings from 
brain imaging are nonetheless informative and account 
for around 40% of the variance in explaining the presence 
of depression.115 A similar percentage has been reported 
for a miscellany of psychosocial factors.116 The deleterious 
effects of depression on patients with multiple sclerosis 
are substantial (panel 3). Not only is it associated with an 
increased suicide rate compared with that in the general 
population,117 but it is also a major determinant of quality 
of life.118 Therefore, the fact that depression is often 
overlooked in neurological clinics and, even when 
detected, inadequately treated, is worrying.119 Recently 
published treatment guidelines from the American 
Academy of Neurology, however, draw attention to the 
dearth of empirical data to guide treatment decisions.59 A 
Cochrane review of antidepressant medication for 
multiple sclerosis-related depression noted modest 
benefits and prominent side-effects.57 A second Cochrane 
review that focused on various forms of psychotherapy 
for patients with multiple sclerosis was more enthusiastic 
about cognitive behavioural therapy.58 The American 
Academy of Neurology also cautiously endorsed cognitive 
behavioural therapy, even when given over the telephone 
(panel 3)—a finding that has practical implications for 
patients with progressive multiple sclerosis whose high 
degree of neurological impairment can prove a barrier to 
attending regular clinic-based treatment.59 Unfortunately, 
this piece of logistical good news does not necessarily 
make cognitive behavioural therapy an effective treatment 
of choice for depressed patients with progressive multiple 
sclerosis. As is the case for published studies on cognitive 
rehabilitation, the findings are again weighted appreciably 
in favour of individuals with RRMS. It therefore remains 
unclear whether cognitive dysfunction, which is more 
frequent and extensive in progressive multiple sclerosis, 
presents an obstacle to cognitive behavioural therapy, if 
not an insuperable barrier. Finally, although the exercise 
treatment data for multiple sclerosis-related depression 
are generally mixed,120 the one study that limited 
enrolment to patients with SPMS reported an 
improvement in mood as one of the secondary 
outcome measures.25
In summary, although cognitive behavioural therapy is 
an effective treatment for depression in multiple sclerosis, 
it is premature to conclude that the benefits apply to 
patients with progressive disease. No firm conclusions 
can be drawn in relation to antidepressants and exercise 
as effective treatments in progressive disease.
Pseudobulbar affect
Pseudobulbar affect (pathological laughing and crying), 
which is present in up to 10% of patients with multiple 
sclerosis, mainly occurrs in patients with SPMS.20 
Treatment guidelines suffer less from the equivocation 
that bedevils cognition and depression. A combination of 
dextromethorphan and quinidine is endorsed in the 
American Academy of Neurology’s recommendations.59
In summary, dextromethorphan with quinidine is 
likely to be an effective treatment for pseudobulbar affect 
in progressive multiple sclerosis.
Conclusions
When the focus falls on progressive multiple sclerosis, 
the designation of disease course can prove challenging, 
especially for defining the point at which RRMS 
transitions into SPMS. All studies of progressive multiple 
sclerosis confront this problem and our Series paper is 
no exception. With this potential limitation in mind, 
some common threads run through our review of 
symptomatic treatment studies for progressive multiple 
sclerosis. The main finding to emerge is that studies 
devoted solely to patients with SPMS or PPMS are scarce 
(table 2). Furthermore, when patients with progressive 
disease are included alongside those with RRMS, the 
number of patients is usually very small and analysis of 
treatment effects does not take into account the possible 
Panel 3: Case study 3—depression
A 34-year-old married woman with a 12-year history of multiple sclerosis that had 
entered a secondary progressive phase 5 years ago was referred for psychiatric assessment 
because of low mood. Her Expanded Disability Status Scale score was 5·0 and she needed 
a walker to walk because of increasingly poor balance. Her history showed she had to stop 
working because of her tremor and increasingly frequent falls. She dated her low mood 
from this time. In addition to experiencing persistent sadness, she reported a loss of 
enjoyment of life, early morning waking, loss of interest in sex, what she called “comfort 
eating” with a 10 lb weight gain, a sense of frustration at finding herself at home alone 
while all her friends were working, and a dip in self-esteem, but no suicidal thoughts. She 
was diagnosed with major depression and offered a choice of two treatments: either 
antidepressant medication or cognitive behavioural therapy. She chose antidepressant  
medication because she viewed it as the simpler of the options and one that did not need 
weekly therapy sessions. One month after starting 20 mg citalopram once daily, a 
selective serotonin reuptake inhibitor, she returned for psychiatric follow-up. Her mood 
was reported to be marginally better and sleep had improved, but dry mouth, 
constipation, and low-grade nausea were troubling side-effects. A decision was made to 
stay with the treatment with the expectation that side-effects would diminish with time. 
By her 2-month follow-up, some further improvements in mood and sleep had occurred, 
but the nausea had become too unpleasant to tolerate and although this had the 
unforeseen effect of reducing appetite with concomitant weight loss, she requested that 
the medication be stopped. The patient was then offered a switch to mirtazepine, a 
noradrenergic and specific serotonin reuptake inhibitor with few gastrointestinal 
side-effects. However, after weighing up the benefits of treatment, which also included a 
low prevalence of sexual side-effects, against potential adverse reactions such as sedation 
and increased appetite, the patient decided to try cognitive behavioural therapy instead. 
Since she lived some distance away from the clinic and was unable to drive because of her 
multiple sclerosis, she would have had difficulty managing the weekly cognitive 
behavioural therapy clinic appointments, the therapy was offered over the telephone. 
After a 12-week course of treatment, her mood was substantially better and the 
medication side-effects had abated. A 6-month follow-up visit showed that mood 
remained largely euthymic. Bouts of despondency, although still present, were infrequent 
and short lived, resolving within hours. The patient had regained her libido and was 
planning on becoming more involved in community activities.
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effect of disease course. Finally, in those few studies in 
which benefits of treatment are noted for patients with 
progressive disease, uncertainty remains regarding the 
ecological validity of the results.
It therefore seems logical that in charting the way 
forward, efforts should be made to address each of these 
deficiencies. Focused interventions on well defined 
subgroups of patients (SPMS, PPMS, Expanded 
Disability Status Scale scores of 4–6 and >6) can provide 
answers fairly quickly. However, as our patients with 
SPMS constantly remind us, the clock is ticking, time is 
short, and the wheelchair waits. Therefore, further 
effort is needed—a bolder approach that combines 
more than one intervention with the aim of producing 
synergistic effects, with an improvement in one area 
boosting the putative benefits of therapy in another, so 
that the overall outcome exceeds the sum of the 
individual treatments. Such an approach often reflects 
the clinical reality of progressive multiple sclerosis in 
which several neurological difficulties rather than an 
isolated problem need to be addressed. To a limited 
degree, this approach has already been tried and the 
results are a source of cautious optimism.106 What is 
now needed are similar initiatives, but on a much bigger 
scale, powered to ensure that final conclusions and 
recommendations are not undercut by sample size 
concerns. However, what might ultimately prove to be 
the most effective strategy could be a combination of 
multidisciplinary rehabilitative inter ventions plus new 
treatments directly addressing neurodegenerative 
processes such as oxidative stress and damage.121 Studies 
like these will be complicated, costly, and logistically 
challenging. Yet these barriers need to be overcome. 
The Progressive Multiple Sclerosis Alliance, a coming 
together of multiple sclerosis societies from eight 
countries in association with the Multiple Sclerosis 
International Federation, endorses such an approach. 
In the absence of effective disease-modifying drugs, a 
combination of potentially synergistic treatments could 
offer the best opportunity yet to alleviate symptoms and 
improve function.
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